EX-10 9 filename9.htmLetter Agreement • July 21st, 2023
Contract Type FiledJuly 21st, 2023This amended and restated letter agreement (including all appendices and attachments hereto, the “Letter Agreement”) is entered into on November 7, 2013 and effective as of September 12, 2012, in connection with the investment by the Bill & Melinda Gates Foundation (the “Foundation”), a Washington charitable trust that is a tax-exempt private foundation, of a total of six million and eight hundred thousand dollars ($6,800,000) for Series A Preferred Stock of Visterra, Inc. (the “Company”) at the per share price of $1.00 (the “Foundation Investment”). This Letter Agreement replaces the letter agreement, dated September 12, 2012, between the Company and the Foundation in its entirety. The Foundation is making the Foundation Investment in accordance with the provisions of the investment documents executed in connection with the closing of the supplemental Series A Preferred Stock offering (“Supplemental Closing”), including, without limitation, the Amended and Restated Series A Convertibl
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.Letter Agreement • January 5th, 2016 • Visterra, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJanuary 5th, 2016 Company Industry JurisdictionThis amended and restated letter agreement (including all appendices and attachments hereto, the “Letter Agreement”) is entered into on November 7, 2013 and effective as of September 12, 2012, in connection with the investment by the Bill & Melinda Gates Foundation (the “Foundation”), a Washington charitable trust that is a tax-exempt private foundation, of a total of six million and eight hundred thousand dollars ($6,800,000) for Series A Preferred Stock of Visterra, Inc. (the “Company”) at the per share price of $1.00 (the “Foundation Investment”). This Letter Agreement replaces the letter agreement, dated September 12, 2012, between the Company and the Foundation in its entirety. The Foundation is making the Foundation Investment in accordance with the provisions of the investment documents executed in connection with the closing of the supplemental Series A Preferred Stock offering (“Supplemental Closing”), including, without limitation, the Amended and Restated Series A Convertibl